Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 8/20 | 0.53 |
| ▸ | KDR | P35968 | 7/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.48 |
| ▸ | KIF5B | P33176 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5492065 | 0.85 | TRPA1 (0.60) | TRPA1EGFRKDRRETKDM1A | |
| SCHEMBL4419720 | 0.76 | EGFR (0.48) | TRPA1EGFRKDRRETKDM1A | |
| SCHEMBL23721045 | 0.76 | KDR (0.58) | EGFRKDRKDM1ALCKRAF1 | |
| SCHEMBL4417714 | 0.75 | TRPA1 (0.47) | TRPA1EGFRKDRRETKDM1A | |
| SCHEMBL16760478 | 0.75 | KDR (0.64) | TRPA1EGFRKDRRETKIF5B | |
| SCHEMBL20897402 | 0.73 | KDR (0.52) | TRPA1EGFRKDRRETKDM1A | |
| SCHEMBL4421666 | 0.72 | TRPA1 (0.63) | TRPA1EGFRKDRRETERBB2 | |
| SCHEMBL4375675 | 0.72 | TRPA1 (0.63) | TRPA1EGFRKDRRETERBB2 | |
| SCHEMBL4417741 | 0.72 | EGFR (0.53) | EGFRKDRRETKIF5BCSF1R | |
| SCHEMBL3951030 | 0.72 | ENPP1 (0.73) | EGFRKDRRETKIF5BCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | TRPA1 2378/4885EGFR 1578/4885KDR 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.